JP2022522815A5 - - Google Patents
Info
- Publication number
- JP2022522815A5 JP2022522815A5 JP2021551926A JP2021551926A JP2022522815A5 JP 2022522815 A5 JP2022522815 A5 JP 2022522815A5 JP 2021551926 A JP2021551926 A JP 2021551926A JP 2021551926 A JP2021551926 A JP 2021551926A JP 2022522815 A5 JP2022522815 A5 JP 2022522815A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- sequence number
- composition according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962817152P | 2019-03-12 | 2019-03-12 | |
| US62/817,152 | 2019-03-12 | ||
| PCT/CA2020/050321 WO2020181376A1 (en) | 2019-03-12 | 2020-03-11 | Tsg-6 antibodies and uses therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022522815A JP2022522815A (ja) | 2022-04-20 |
| JP2022522815A5 true JP2022522815A5 (https=) | 2023-03-20 |
Family
ID=72427149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021551926A Pending JP2022522815A (ja) | 2019-03-12 | 2020-03-11 | Ｔｓｇ－６抗体およびその用途 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220153834A1 (https=) |
| EP (1) | EP3938389A4 (https=) |
| JP (1) | JP2022522815A (https=) |
| KR (1) | KR20210138674A (https=) |
| CN (1) | CN113748130A (https=) |
| AU (1) | AU2020234533A1 (https=) |
| BR (1) | BR112021017810A2 (https=) |
| CA (1) | CA3129302A1 (https=) |
| EA (1) | EA202192488A1 (https=) |
| IL (1) | IL286216A (https=) |
| MX (1) | MX2021010766A (https=) |
| SG (1) | SG11202109708TA (https=) |
| TW (1) | TW202100551A (https=) |
| WO (1) | WO2020181376A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023192829A2 (en) * | 2022-03-28 | 2023-10-05 | University Of Florida Research Foundation, Incorporated | Alpha-1 antitrypsin z- and m-specific binding proteins |
| TWI876557B (zh) * | 2022-09-30 | 2025-03-11 | 臺北醫學大學 | 用於前列腺癌診斷和早期發病的單株抗體 |
| KR102582500B1 (ko) | 2022-10-27 | 2023-09-26 | 서울대학교산학협력단 | Tnfaip6 -조작된 종양 세포 및 이의 이용 |
| WO2024102759A1 (en) * | 2022-11-07 | 2024-05-16 | Board Of Regents, The University Of Texas System | Methods involving detecting tnf stimulated gene 6 (tsg-6) for improving anti-tumor responses to immune therapy in cancer patients |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2896058A1 (en) * | 2012-12-24 | 2014-07-03 | Abbvie Inc. | Prolactin receptor binding proteins and uses thereof |
| AU2015301338C1 (en) * | 2014-08-04 | 2021-07-22 | Baylor Research Institute | Antagonistic anti-OX40L antibodies and methods of their use |
| PT3186281T (pt) * | 2014-08-28 | 2019-07-10 | Halozyme Inc | Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica |
-
2020
- 2020-03-11 US US17/434,368 patent/US20220153834A1/en not_active Abandoned
- 2020-03-11 CA CA3129302A patent/CA3129302A1/en active Pending
- 2020-03-11 JP JP2021551926A patent/JP2022522815A/ja active Pending
- 2020-03-11 KR KR1020217032689A patent/KR20210138674A/ko not_active Ceased
- 2020-03-11 SG SG11202109708T patent/SG11202109708TA/en unknown
- 2020-03-11 AU AU2020234533A patent/AU2020234533A1/en active Pending
- 2020-03-11 MX MX2021010766A patent/MX2021010766A/es unknown
- 2020-03-11 TW TW109108016A patent/TW202100551A/zh unknown
- 2020-03-11 WO PCT/CA2020/050321 patent/WO2020181376A1/en not_active Ceased
- 2020-03-11 EA EA202192488A patent/EA202192488A1/ru unknown
- 2020-03-11 BR BR112021017810A patent/BR112021017810A2/pt unknown
- 2020-03-11 CN CN202080028139.0A patent/CN113748130A/zh active Pending
- 2020-03-11 EP EP20769649.3A patent/EP3938389A4/en not_active Withdrawn
-
2021
- 2021-09-09 IL IL286216A patent/IL286216A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240025980A1 (en) | Therapeutic targeting of non-cellular structures | |
| US20220281992A1 (en) | Targeted chimeric proteins and uses thereof | |
| JP2024028543A (ja) | 二官能性タンパク質およびその作製 | |
| JP6152433B2 (ja) | 抗ｔｎｆ−抗ｉｌ−１７二重特異性抗体 | |
| JP2022522815A5 (https=) | ||
| JP2020520665A5 (https=) | ||
| JP7766392B2 (ja) | 治療用抗ｃｄ４０リガンド抗体 | |
| JP2018510617A5 (https=) | ||
| JP2019521647A5 (https=) | ||
| US11851485B2 (en) | Engineered anti-IL-2 antibodies | |
| US20260109748A1 (en) | Modulation of dendritic cell lineages | |
| CN105358175B (zh) | 用于治疗硬皮病的抗ccl2和抗loxl2组合疗法 | |
| JP2021193121A (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| JP6192862B2 (ja) | Ｆｃ融合高親和性ＩｇＥ受容体α鎖 | |
| JP2019162119A5 (https=) | ||
| JP7793511B2 (ja) | Ｐｄ－ｌ１標的化キメラタンパク質及びその使用 | |
| JP2022517809A5 (https=) | ||
| TW202332691A (zh) | Ige調節的疾病的治療 | |
| CN106573059A (zh) | 接受过抗TNF‑α抗体疗法的银屑病患者的治疗方法 | |
| TW202539734A (zh) | 使用白細胞介素-17（il-17）拮抗劑治療自體免疫性疾病之方法 | |
| JP2019518473A5 (https=) | ||
| JP2021533806A5 (https=) | ||
| JP2022520817A5 (https=) | ||
| TW202114734A (zh) | Il-17拮抗劑治療自身免疫疾病的方法 | |
| NZ772900A (en) | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |